Wave Life Sciences Reports Dose-Dependent Activin E Reductions Up to 85% with WVE-007 in Obesity Trial
核心洞察
Wave Life Sciences announced dose-dependent Activin E (搜索) reductions of up to 85% one month after a single dose of WVE-007 in the INLIGHT clinical trial for obesity (搜索) treatment.
The reductions observed in higher dose cohorts exceeded levels that led to weight loss in preclinical models, with sustained effects lasting six months in the lowest dose cohort.
WVE-007 demonstrated a favorable safety profile and aims to achieve fat loss comparable to semaglutide through a novel INHBE silencing mechanism that preserves muscle mass.
Wave Life Sciences Ltd. reported significant dose-dependent target engagement data from its INLIGHT clinical trial of WVE-007, a GalNAc-siRNA designed for obesity (搜索) treatment. The biotechnology company announced Activin E (搜索) reductions of up to 85% one month after single-dose administration, exceeding levels that led to weight loss in preclinical models.
Robust Target Engagement Across Dose Cohorts
The INLIGHT trial, evaluating WVE-007 in a 3:1 active-to-placebo design, demonstrated highly significant Activin E (搜索) reductions across three dose cohorts at day 29 post-administration (p<0.0001 for all doses):
- Cohort 3 (400 mg): 85% reduction
- Cohort 2 (240 mg): 75% reduction
- Cohort 1 (75 mg): 56% reduction
The durability of target engagement proved particularly noteworthy in Cohort 1, where Activin E (搜索) reductions were sustained throughout the six-month follow-up period, supporting the potential for once or twice yearly dosing regimens.
"We are incredibly excited to be observing potent, durable, and dose-dependent Activin E (搜索) reductions with just single doses of WVE-007 in the first three cohorts of our INLIGHT clinical trial for obesity (搜索)," said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "This indicates our preclinical data are translating and affirms we have a potential best-in-class RNAi modality enabled by our proprietary chemistry, including PN."
Novel Mechanism Targets Fat Loss While Preserving Muscle
WVE-007 employs an INHBE silencing approach based on human genetics research showing that individuals with naturally low INHBE levels exhibit lower visceral fat, reduced fasting glucose and triglycerides, and decreased risk of type 2 diabetes (搜索) and cardiovascular disease (搜索). The therapeutic aims to reduce Activin E (搜索) levels to induce fat loss without impacting muscle mass.
Preclinical studies in diet-induced obesity (搜索) mouse models demonstrated that single doses of GalNAc INHBE-siRNA produced Activin E (搜索) reductions greater than 70% and weight loss driven by visceral fat reduction without affecting muscle mass. The reduced Activin E levels led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue.
Safety Profile and Clinical Development Timeline
WVE-007 has demonstrated a favorable safety and tolerability profile to date, with an independent data monitoring committee supporting dose expansion of the 600 mg cohort and escalation beyond that level. The company aims for WVE-007 to achieve fat loss comparable to semaglutide by six months following a single dose.
Wave Life Sciences has outlined multiple upcoming clinical data readouts from INLIGHT:
- Q4 2025: Three-month follow-up data from expanded Cohort 2 (240 mg) and additional data from Cohort 1 (75 mg)
- Q1 2026: Six-month follow-up data from Cohort 2 and three-month data from Cohort 3
- Q2 2026: Six-month follow-up data from Cohort 3 and three-month data from Cohort 4
Expanding RNA Medicine Pipeline
Beyond WVE-007, Wave Life Sciences announced the selection of WVE-008 (搜索) as its clinical candidate for PNPLA3-I148M liver disease (搜索), with an estimated 9 million homozygous PNPLA3-I148M individuals affected by liver disease in the U.S. and Europe. The company expects to file a Clinical Trial Application for WVE-008 in 2026.
The company also reported progress with WVE-006 for alpha-1 antitrypsin deficiency (搜索) (AATD (搜索)), which has achieved key treatment goals by restoring protein levels associated with lower risk of AATD liver and lung diseases. Total AAT levels reached 13 μM, with wild type M-AAT protein accounting for 64% of circulating total AAT after treatment.
Wave Life Sciences is pioneering a new modality that combines editing and silencing capabilities in a single oligonucleotide construct, with preclinical data demonstrating simultaneous LDLR (搜索) protein upregulation and PCSK9 mRNA silencing using a single GalNAc-oligonucleotide construct.